News
UPPSALA, Sweden, April 10, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback